Manufacturing

Ross Charles’ 300-gallon process vessel is suitable for 5-psi internal pressure at 300 °F and is agitated by a disperser blade driven to 1150 rpm by a 75HP explosion-proof motor.

The ÄKTA pilot 600 from GE Healthcare is a lightweight bench-top chromatography system suited to streamline both GMP and non-GMP everyday operations.

Endress+Hauser’s Field Xpert SMT70 is a tablet PC suited for commissioning and maintaining field instruments in hazardous and non-hazardous locations.

Leistritz has added a continuous twin screw extrusion system that continuously mixes and conditions gel-mass formulations designed to replace previous upstream batch processing methodologies.

Demand for direct-to-patient services is exploding. Michael Sweeney, senior director of patient-centric logistics at World Courier, discusses issues that the new model presents.

By minding knowledge gaps, bio/pharma companies can avoid development pitfalls.

From separation systems to reactor technology, new tools are increasing the feasibility of continuous API production.

Catalent’s GPEx technology was used to develop antibody for anti-methamphetamine clinical study.

TxCell announces manufacturing agreement with Lonza for its HLA-A2 CAR-Treg cellular product.

FUJIFILM Diosynth Biotechnologies opens Cambridge, MA center to promote collaboration with biotech companies.

Bosch Packaging Technology will introduce its newest R&D device for continuous oral solid dosage production at Achema 2018.

Rentschler Fill Solutions and Ultragenyx announce fill and finish agreement for the US commercial supply of Mepsevii.

Ingenza, in partnership with the University of Dundee and Drochaid Research Services, will work on a project to recycle CO2 emissions from bioprocessing plants to serve as feedstock and energy inputs.

Coperion will be presenting a new, innovative pneumatic conveying process for plastic pellets that consumes up to 35% less power and generates up to 98% less dust at Achema 2018. Fluidlift ecoblue enables manufacturers of plastic granulates to increase product quality while reducing specific power consumption.

The UK’s University of Sheffield opened a new chemical engineering teaching plant for continuous oral solid-dosage pharmaceuticals using GEA’s multipurpose platform.

Bosch Packaging Technology’s capsule filling machine for small batches of hard capsules uses a fully automated, washable containment process.

The updated version of Schubert-Pharma’s Flowmodul unit for packing units into flowpacks features cleanability.

Bosch Packaging Technology will present its new modular freeze dryer at Achema 2018.

GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.

This marks the third FDA approval for the company’s second biomanufacturing plant in Incheon, Korea.

The European Commission has approved Zessly (infliximab), a biosimilar to Johnson & Johnson’s blockbuster Remicade (infliximab).

Glatt Ingenieurtechnik has added compact continuous agglomeration equipment and new control systems to its "modular plant engineering" portfolio.

Optima will also display the freeze dryer CS and the sterility test isolator STISO at the show.

The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.

The sterility test isolator (STISO) for testing aseptically filled drug products and for testing toxic aseptic drugs (STISOtox) from Metall+Plastic, a subsidiary of Optima, are modular and ergonomically designed.

GEA and Perceptive Engineering will collaborate to promote and deploy multivariate monitoring and advanced process control (APC) solutions for batch and continuous pharmaceutical process units.

In adding a Vanrx Pharmasystems aseptic filling isolator, FUJIFILM adds fill/finish for gene therapies and viral vaccines.

WuXi Biologics will build a biologics manufacturing facility in Singapore that will use both fed-batch and continuous perfusion-based single-use bioreactors.

The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.

The company has leased and purchased facilities in the United States and Europe to expand its cell therapy pipeline.